May 19, 2020 | COVID-19, Disease Area Trends
Here is a quick update on the ever-evolving world of COVID-19 trials. Since our initial posting on this topic three weeks ago, the number of trials has grown from 100 to over 300. The number of clinical facilities with clinical trials for COVID-19 has grown from 160...
May 1, 2020 | COVID-19, Disease Area Trends
We all know the basics for fighting the COVID-19 virus, like washing our hands and staying socially distant from one another, but what about future vaccines and treatments? There is a lot of talk right now about different companies making progress and potential...
Nov 16, 2017 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...
Oct 19, 2017 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
Aug 28, 2017 | Business, Data Analytics, Diabetes, Disease Area Trends
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Aug 4, 2017 | Chronic Disease, Diabetes, Disease Area Trends
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next...
